Belumosudil mesylate
Modify Date: 2024-01-10 15:30:50
Belumosudil mesylate structure
|
Common Name | Belumosudil mesylate | ||
|---|---|---|---|---|
| CAS Number | 2109704-99-4 | Molecular Weight | 548.61 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C27H28N6O5S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Belumosudil mesylateBelumosudil mesylate (KD025 mesylate) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties[1]. |
| Name | Belumosudil mesylate |
|---|
| Description | Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties[1]. |
|---|---|
| Related Catalog | |
| Target |
ROCK2:105 nM (IC50) ROCK1:24 μM (IC50) |
| In Vitro | Belumosudil (SLx-2119; 40 µM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. The microarray hybridized with aRNA from HMVEC treated with Belumosudil, shows a 5-times higher background than the other arrays[1]. |
| In Vivo | Belumosudil (KD-025; 100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. Belumosudil is at least as efficacious in aged, diabetic or female mice, as in normal adult males[2]. |
| References |
| Molecular Formula | C27H28N6O5S |
|---|---|
| Molecular Weight | 548.61 |